W H I T E P A P E R

COPD & Chronic Lung Disease

The Slow Path to Respiratory Dependency

Emphysema · Chronic Bronchitis · Pulmonary Fibrosis · Bronchiectasis · Severe Asthma

A Complete Guide for Patients, Families, and Caregivers

Diagnosis · Medications & Devices · Oxygen & Pulmonary Rehab · Caregiver Support

Published July 2026 | Health Education Resource Center

Sources: GOLD, ATS, American Lung Association, COPD Foundation, NIH NHLBI, CDC, FDA

> *This white paper is for educational purposes only and does not constitute medical or legal advice. Consult qualified medical professionals for personal guidance.*

1. EXECUTIVE SUMMARY

Chronic obstructive pulmonary disease (COPD) and the broader family of chronic lung diseases are among the quietest drivers of dependency in older adults. Unlike a stroke or a hip fracture, lung disease rarely produces a single dramatic event that ends independence. Instead, it works by degrees — a stair gets harder, then bathing becomes exhausting, then a portable oxygen tank becomes a permanent accessory, then the patient cannot safely live alone.

By the time most families recognize what is happening, the patient has already moved through several stages of functional loss. Each severe exacerbation — a flare bad enough to require the emergency department or hospital — leaves the patient at a permanently lower functional level than before. Recovery to baseline is often partial; recovery to the level of two flares ago is rare.

COPD is the fifth leading cause of death in the United States. More than 16 million Americans are diagnosed; the CDC estimates roughly as many again are undiagnosed and undertreated. Idiopathic pulmonary fibrosis (IPF) carries a median survival of just 3–5 years after diagnosis. Bronchiectasis prevalence is rising approximately 8% per year. Severe, uncontrolled asthma still kills roughly 3,500 Americans each year and accounts for far more disability than is generally recognized.

Key Facts at a Glance

- **Prevalence:** 16+ million Americans diagnosed with COPD; a similar number are believed to be undiagnosed. Approximately 250,000 Americans live with pulmonary fibrosis.
- **Function:** By modified MRC (mMRC) Dyspnea Grade 3, patients cannot walk 100 yards without stopping for breath. By Grade 4, they are breathless dressing themselves.
- **Exacerbations:** Roughly 20% of COPD patients hospitalized for a flare are readmitted within 30 days. Each severe exacerbation is associated with roughly 87 mL/year of additional FEV_1 loss on top of normal aging.
- **IPF:** Median survival 3–5 years from diagnosis without treatment; antifibrotics slow but do not stop decline.
- **The good news:** Pulmonary rehabilitation reduces hospitalizations and dyspnea more than any medication. Three new biologic/small-molecule COPD therapies were FDA-approved in 2024–2025. Nerandomilast (Jascayd), the first new IPF drug in more than a decade, was approved in October 2025.

> *Chronic lung disease is one of the most preventable causes of respiratory dependency — yet only about 3–5% of eligible Medicare patients ever enroll in pulmonary rehabilitation. Recognition is early. Referral is late. Families who fare best learn what the mMRC grade means, act on exacerbations before they become admissions, and mobilize palliative care years before hospice becomes necessary.*

2. UNDERSTANDING CHRONIC LUNG DISEASE

Chronic lung disease is a family of overlapping conditions that share one final common pathway: reduced ability to move air and reduced ability to move oxygen from the air into the bloodstream. Some are primarily obstructive (COPD, asthma); some are primarily restrictive (pulmonary fibrosis); some are mixed (bronchiectasis, alpha-1 antitrypsin deficiency). Understanding which one a patient has drives everything that follows.

The Scale of the Problem

16+ million Americans diagnosed with COPD (CDC)

~16 million estimated to have COPD but remain undiagnosed

~250,000 Americans living with pulmonary fibrosis

~25 million Americans with asthma, of whom 5–10% have severe or difficult-to-control disease

#5 COPD ranks fifth among leading causes of death in the U.S.

The Family of Chronic Lung Diseases

Chronic Obstructive Pulmonary Disease (COPD)

COPD is a persistent, largely irreversible airflow limitation caused by damage to the small airways (chronic bronchitis) and destruction of the alveoli (emphysema). Cigarette smoking is the dominant cause in the United States, but environmental and occupational exposures — biomass smoke, dust, industrial fumes — cause many cases, and a smaller subset is driven by genetic alpha-1 antitrypsin deficiency. Airflow limitation is measured by spirometry (FEV_1/FVC ratio less than 0.70 after a bronchodilator).

Idiopathic Pulmonary Fibrosis (IPF)

IPF is a progressive scarring disease of the lung interstitium — the delicate tissue where oxygen crosses into the bloodstream. Median survival without antifibrotic treatment is 3–5 years. Two antifibrotics (pirfenidone, nintedanib) slow decline; a third (nerandomilast) was approved October 2025 and is the first new mechanism in more than a decade. Diagnosis is by high-resolution CT showing a usual interstitial pneumonia (UIP) pattern, sometimes supplemented by lung biopsy.

Bronchiectasis

Bronchiectasis is permanent, abnormal widening of the airways, usually with chronic infection and daily mucus production. Prevalence is rising approximately 8% per year, driven in part by better diagnosis and by nontuberculous mycobacterial (NTM) infection. Airway clearance techniques and targeted antibiotics are the mainstay of treatment.

Severe and Uncontrolled Asthma

Approximately 5–10% of asthma patients have disease that remains poorly controlled despite high-dose inhaled therapy. This severe phenotype is now the domain of biologic therapies (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) that target specific inflammatory pathways. Uncontrolled asthma still causes preventable deaths and functional loss in older adults.

Other Important Conditions

- Alpha-1 antitrypsin deficiency — an under-recognized genetic cause of early-onset emphysema; a one-time blood test is all it takes to diagnose
- Combined pulmonary fibrosis and emphysema (CPFE) — overlaps two disease processes and behaves worse than either alone
- Occupational lung disease — silicosis, coal workers' pneumoconiosis, asbestosis, hypersensitivity pneumonitis
- Pulmonary hypertension — often complicates advanced lung disease and adds right-heart failure to the clinical picture

3. THE DEPENDENCY CASCADE

Chronic lung disease is unusual among dependency-causing conditions in that it produces functional loss through breathlessness rather than through paralysis, cognitive loss, or fracture. The end result — inability to perform Activities of Daily Living — is the same. The path is slower, and easier to ignore until it is too late to plan.

The mMRC Dyspnea Scale — The Critical Map

The Modified Medical Research Council (mMRC) Dyspnea Scale is the single most useful tool families have for tracking how lung disease is actually affecting daily life. Every Parkinson's patient has a Hoehn & Yahr stage; every COPD patient should have a known mMRC grade. It maps cleanly to functional independence.

Grade	What the Patient Reports	Functional Reality
0	Breathless only with strenuous exercise	Fully independent
1	Short of breath hurrying or walking up a slight hill	Independent; mild fitness loss
2	Walks slower than peers, or stops for breath at own pace	Beginning loss of community independence
3	Stops for breath after ~100 yards or a few minutes	Beginning to need help with shopping, errands
4	Too breathless to leave the house; breathless dressing	Dependent for most ADLs

> *By mMRC Grade 4, the patient is breathless putting on a shirt. Help with bathing, dressing, and toileting is no longer a future concern — it is the current reality. Recognizing the trajectory earlier — at Grade 2 or 3 — is what gives families time to organize care, home modifications, and support before the crisis hits.*

Why Exacerbations Are the Real Enemy

A COPD exacerbation — a sudden worsening of cough, mucus, and breathlessness severe enough to need urgent treatment — is not a temporary setback. The evidence is clear:

- Mean FEV_1 does not return to pre-exacerbation levels even 8 weeks after the event
- 38% of patients hospitalized for a COPD exacerbation show meaningful functional decline 12 weeks later

- Each hospitalization is associated with approximately 87 mL/year of additional FEV_1 loss — on top of normal aging
- Roughly 19.6% of COPD patients are readmitted within 30 days of discharge
- Mortality risk is highest in the 90 days after a severe exacerbation

This is why prevention of exacerbations — not just treatment of them — is the central goal of modern COPD therapy. Every prevented exacerbation preserves function the patient already has. Every exacerbation that occurs accelerates the slide toward dependency.

Oxygen, Mobility, and the Living Environment

As disease progresses, the patient's world physically shrinks:

- **Stair climbing fails first.** Two-story homes become a problem. Beds get moved downstairs. The upstairs bathroom is abandoned.
- **Bathing becomes high-risk.** The combination of humidity, exertion, and reaching overhead produces severe dyspnea. Falls in the shower become common.
- **Home oxygen arrives.** Stationary concentrators sit in the living room; portable units travel with the patient. Tubing tracks become permanent fixtures.
- **Driving stops.** Oxygen-dependent patients lose driving privileges or self-restrict because of fatigue and the risk of severe dyspnea behind the wheel.
- **End-stage care arrives at home or in a facility.** Bedside commodes, hospital beds, BiPAP at night, and 24-hour caregivers — or a transfer to an assisted-living or skilled-nursing setting.

The Right-Heart Complication

Long-standing low oxygen levels force the right side of the heart to pump against high pressures in the pulmonary circulation. Over years, this produces pulmonary hypertension and right heart failure (cor pulmonale). Once cor pulmonale develops, leg swelling, abdominal swelling, and severe fatigue add to the breathlessness — and care needs multiply.

4. DIAGNOSIS AND ASSESSMENT

Spirometry — The Foundational Test

Spirometry — a simple, non-invasive breathing test — is the diagnostic gold standard for COPD and the single most useful lung function measurement across all chronic lung diseases. A post-bronchodilator FEV_1/FVC ratio less than 0.70 establishes obstructive airflow limitation. The FEV_1 percent predicted then grades severity. Every patient with unexplained dyspnea, a smoking history, or occupational exposure should have spirometry. Undertesting is the largest single reason so much COPD remains undiagnosed.

GOLD ABE Assessment (2023 Onward)

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 revision simplified COPD categorization from four groups (ABCD) to three (ABE) — recognizing that any patient with two or more moderate exacerbations, or one hospitalization, needs aggressive management regardless of symptom score.

Group	Symptoms	Exacerbations in past year	Initial Therapy Priority
A	Low (mMRC 0–1)	0 or 1 without hospitalization	A bronchodilator
B	High (mMRC ≥ 2)	0 or 1 without hospitalization	LABA + LAMA
E	Any	≥ 2 moderate or ≥ 1 hospitalization	LABA + LAMA; add ICS if eos ≥ 300

Symptom Tools

- mMRC Dyspnea Scale — 0 to 4, mapped in Section 3
- COPD Assessment Test (CAT) — 8-item questionnaire, score 0–40, tracks symptom burden over time
- Clinical COPD Questionnaire (CCQ) — 10-item alternative used in some settings

6-Minute Walk Test (6MWT)

The 6-minute walk test measures how far a patient can walk in 6 minutes on a flat surface and how much their oxygen saturation drops during exertion. Values under 350 meters, or oxygen desaturation below 88%, signal advanced disease and predict mortality independent of FEV_1.

DLCO and Full Pulmonary Function Testing

Diffusing capacity (DLCO) measures how efficiently oxygen crosses from the alveoli into the bloodstream — the single most sensitive marker for emphysema severity and for the interstitial lung diseases. Full pulmonary function testing includes spirometry, lung volumes, and DLCO.

High-Resolution CT (HRCT) Scan

HRCT visualizes emphysema pattern, small-airway disease, bronchiectasis, and interstitial fibrosis. A usual interstitial pneumonia (UIP) pattern on HRCT is often sufficient to diagnose IPF without lung biopsy.

Alpha-1 Antitrypsin Screening

A one-time blood test that identifies the roughly 1 in 25 COPD patients whose disease is driven or accelerated by alpha-1 antitrypsin deficiency. Every patient with COPD should be tested at least once — especially those with early-onset disease, disease disproportionate to smoking history, or a family history of lung or liver disease.

Oxygen Assessment

Measuring oxygen saturation at rest, with exertion, and during sleep identifies patients who qualify for home oxygen therapy. Medicare coverage criteria include resting oxygen saturation ≤ 88%, or ≤ 89% with cor pulmonale, secondary erythrocytosis, or evidence of pulmonary hypertension.

Functional Assessment for Dependency

For patients and families navigating functional loss, the critical clinical findings are: mMRC grade 3 or higher, oxygen dependence, frequent exacerbations, and the loss of two or more Activities of Daily Living. Any of these signals that the patient has either crossed the threshold into dependency now — or will within months.

5. MEDICATIONS FOR CHRONIC LUNG DISEASE (2026)

The COPD treatment landscape has changed dramatically in the past two years. Three landmark FDA approvals — ensifentrine (Ohtuvayre) in June 2024, dupilumab (Dupixent) for COPD in September 2024, and mepolizumab (Nucala) for COPD in May 2025 — represent the most significant pharmacologic advances in COPD in over twenty years. For pulmonary fibrosis, nerandomilast (Jascayd) was approved in October 2025 — the first new IPF therapy in more than a decade. Patients diagnosed with COPD before 2024 deserve a full medication review.

5.1 Short-Acting Rescue Inhalers

Brand Name	Generic Name	Class	Notes
ProAir, Proventil, Ventolin	Albuterol	SABA	Standard quick-relief inhaler for sudden symptoms
Xopenex	Levalbuterol	SABA	Refined isomer; sometimes fewer side effects
Atrovent	Ipratropium	SAMA	Often combined with albuterol (Combivent Respimat)

Rescue inhalers relieve sudden breathlessness within minutes but do not slow disease progression. Frequent use — more than twice a week beyond the prescribed maintenance regimen — signals that controller therapy needs to be intensified.

5.2 Long-Acting Bronchodilators (LABAs and LAMAs)

These are the foundation of daily controller therapy. LABAs (long-acting beta-agonists) relax airway smooth muscle; LAMAs (long-acting muscarinic antagonists) block the parasympathetic constrictor signal.

Brand Name	Generic Name	Class	Dosing
Spiriva / Spiriva Respimat	Tiotropium	LAMA	Once daily — long-standing standard LAMA
Incruse Ellipta	Umeclidinium	LAMA	Once daily
Tudorza Pressair	Aclidinium	LAMA	Twice daily
Lonhala Magnair	Glycopyrrolate	LAMA (nebulized)	For patients who cannot

Brand Name	Generic Name	Class	Dosing
			use handheld inhalers
Serevent	Salmeterol	LABA	Twice daily
Foradil / Perforomist	Formoterol	LABA	Available as nebulized solution
Arcapta	Indacaterol	LABA	Once daily
Striverdi	Olodaterol	LABA	Once daily

5.3 LABA/LAMA Combinations

Combining the two mechanisms in one inhaler is more effective than either alone and reduces exacerbations meaningfully.

Brand Name	Components	Dosing
Anoro Ellipta	Umeclidinium + Vilanterol	Once daily
Stiolto Respimat	Tiotropium + Olodaterol	Once daily
Bevespi Aerosphere	Glycopyrrolate + Formoterol	Twice daily
Duaklir Pressair	Aclidinium + Formoterol	Twice daily

5.4 ICS/LABA Combinations

Inhaled corticosteroids (ICS) added to a LABA reduce exacerbations in patients with eosinophilic inflammation. Used selectively in COPD — not every patient benefits, and ICS carries increased pneumonia risk.

Brand Name	Components	Notes
Advair, Wixela	Fluticasone + Salmeterol	Twice daily; generic available
Symbicort	Budesonide + Formoterol	Twice daily
Breo Ellipta	Fluticasone furoate + Vilanterol	Once daily
Dulera	Mometasone + Formoterol	Twice daily

5.5 Triple Therapy (ICS + LABA + LAMA)

For patients with persistent exacerbations on dual therapy, the addition of an inhaled corticosteroid in a single triple-combination inhaler is now standard.

Brand Name	Components	Device
Trelegy Ellipta	Fluticasone furoate + Umeclidinium + Vilanterol	Once-daily dry powder inhaler
Breztri Aerosphere	Budesonide + Glycopyrrolate + Formoterol	Twice-daily metered-dose inhaler

5.6 Add-On Oral and Maintenance Therapies

- **Roflumilast (Daliresp):** Oral PDE-4 inhibitor for the chronic bronchitis phenotype with frequent exacerbations. Side effects (nausea, diarrhea, weight loss) limit use.
- **Azithromycin maintenance:** Low-dose chronic antibiotic for frequent exacerbators. Reduces exacerbations meaningfully but carries QT-interval and ototoxicity risks.
- **N-acetylcysteine (NAC):** Mucolytic and antioxidant; modest evidence in chronic bronchitis.

5.7 The New Wave — 2024–2026 Approvals

Three approvals in roughly 18 months have transformed what is possible in COPD care. These are biologic and small-molecule therapies that target the underlying biology, not just bronchodilation.

Brand Name	Generic Name	Mechanism	FDA Approval
Ohtuvayre	Ensifentrine (nebulized)	Dual PDE3/PDE4 inhibitor — bronchodilator + anti-inflammatory	June 2024 — first new mechanism in 20+ years
Dupixent	Dupilumab	IL-4 / IL-13 monoclonal antibody for type-2 inflammation COPD	September 2024
Nucala	Mepolizumab	Anti-IL-5 for eosinophilic COPD (blood eos ≥ 150 cells/µL)	May 2025

These three drugs do not replace standard inhaler therapy — they add to it for the right patient. The most important next step for any COPD patient who has not been re-evaluated since 2024 is to ask the pulmonologist: 'Should I be tested for type-2 inflammation or elevated eosinophils, and would Dupixent, Nucala, or Ohtuvayre fit my situation?'

5.8 Pulmonary Fibrosis (IPF) Medications

Brand Name	Generic Name	Mechanism	Notes
Esbriet	Pirfenidone	Antifibrotic	Slows decline in FVC
Ofev	Nintedanib	Tyrosine kinase inhibitor / antifibrotic	Slows decline in FVC; also approved for progressive fibrosing ILD
Jascayd	Nerandomilast	PDE-4B inhibitor	FDA approved October 2025 — first new IPF therapy in 10+ years

5.9 Alpha-1 Antitrypsin Augmentation

Patients with severe alpha-1 antitrypsin deficiency receive weekly intravenous infusions of alpha-1 protein concentrate. Brands include Prolastin-C, Zemaira, Aralast NP, and Glassia. Coverage typically requires documented severe deficiency and evidence of lung disease.

5.10 Home Oxygen Therapy

Supplemental oxygen is the only therapy proven to extend life in patients with chronic hypoxemia. Delivery options include:

- Stationary oxygen concentrators — the household workhorse, plugged into the wall
- Portable oxygen concentrators (POC) — battery-powered, FAA-approved for air travel
- Compressed-gas cylinders — small portable tanks for backup or specific outings
- Liquid oxygen — highest flow capacity; needed for very high oxygen requirements

6. DEVICES, PROCEDURES, AND NON-DRUG INTERVENTIONS

Medications alone cannot manage moderate-to-severe lung disease. The most important interventions are often pulmonary rehabilitation, smoking cessation, and properly fitted oxygen — not the newest inhaler.

6.1 Inhaler Devices and Technique

Studies consistently find that half or more of patients use their inhalers incorrectly. Poor technique means the medication never reaches the airways where it is needed. Every patient should have their technique observed and corrected — by a respiratory therapist, pharmacist, or trained clinician — at every meaningful visit.

- Metered-dose inhalers (MDIs) — coordinated press-and-inhale; a spacer improves delivery
- Dry powder inhalers (DPIs) — require a fast, deep inhalation
- Soft mist inhalers (Respimat) — slower, easier for older patients or those with weak inspiratory flow
- Nebulizers — for patients who cannot coordinate any handheld device

6.2 Pulmonary Rehabilitation — The Most Underused Intervention

Pulmonary rehabilitation is a structured, medically supervised program of exercise, education, breathing training, and nutritional counseling. Evidence shows it reduces dyspnea, improves exercise tolerance, decreases hospitalizations, and improves quality of life more than any single medication. It is covered by Medicare for qualifying patients (typically 36 sessions over about 12 weeks) and by most commercial insurers.

> *Only 3–5% of eligible Medicare patients ever enroll in pulmonary rehabilitation. If your pulmonologist has not offered a referral, ask specifically — this is the highest-yield action a patient with moderate lung disease can take.*

6.3 Non-Invasive Ventilation (NIV / BiPAP)

BiPAP delivers pressure support through a face mask, unloading the tired diaphragm and improving carbon dioxide clearance. It is used at home for stable hypercapnic COPD and in the hospital during acute exacerbations. Home NIV reduces hospitalizations and improves survival in the right patients.

6.4 Bronchoscopic Lung Volume Reduction

For selected patients with severe upper-lobe emphysema and hyperinflation, one-way endobronchial valves (Zephyr Valve, Spiration Valve) placed by bronchoscopy collapse the worst-diseased lobe and allow the healthier lung to expand. Patients selected by strict criteria (heterogeneous emphysema, no

collateral ventilation on Chartis testing, adequate function to survive the procedure) experience meaningful improvements in dyspnea and exercise tolerance.

6.5 Lung Volume Reduction Surgery (LVRS)

Surgical resection of the worst-diseased portions of the lung — a more invasive alternative to endobronchial valves — remains an option for a narrow group of patients with upper-lobe-predominant emphysema and preserved exercise capacity.

6.6 Lung Transplantation

Lung transplant is the ultimate option for advanced COPD, IPF, and other end-stage lung diseases. Selection is strict — age, functional status, comorbidities, and body-mass index all matter. Median post-transplant survival is roughly 6–7 years; one-year survival exceeds 85%. Referral to a transplant center should happen well before the patient is bedbound.

6.7 Smoking Cessation — Still the Single Most Important Intervention

Nothing else in this document matters as much as stopping smoking for a patient who still smokes. Modern smoking cessation combines counseling with pharmacotherapy:

- Combination nicotine replacement — patch plus short-acting (gum, lozenge, inhaler)
- Varenicline (Chantix / Champix) — the most effective monotherapy
- Bupropion (Zyban) — alternative especially useful with concurrent depression
- Free coaching: 1-800-QUIT-NOW (state quitlines) and Smokefree.gov

6.8 Vaccinations

Chronic lung disease patients are at high risk for respiratory infections that trigger exacerbations. Recommended vaccines:

- Annual influenza vaccine
- Pneumococcal vaccines (PCV20 or PCV15 followed by PPSV23)
- RSV vaccine — approved for adults 60+ and older adults at high risk
- COVID-19 vaccine per current CDC guidance
- Tdap (tetanus, diphtheria, pertussis) — once, then Td every 10 years
- Shingles (Shingrix) — for adults 50+

7. CLINICAL TRIALS AND PIPELINE 2026

The lung disease pipeline in 2026 is unusually active. Multiple biologic and small-molecule mechanisms are in Phase 3 for COPD, and IPF is finally seeing renewed development after a long dry spell.

7.1 COPD Pipeline

Drug	Sponsor	Mechanism	Status as of 2026
Tozorakimab	AstraZeneca	Anti-IL-33 monoclonal antibody	First IL-33 inhibitor with 3 positive Phase 3 trials — April 2026
Itepekimab	Regeneron / Sanofi	Anti-IL-33 monoclonal antibody	Mixed Phase 3 — AERIFY-1 met endpoint, AERIFY-2 missed
Astegolimab	Roche / Genentech	Anti-ST2 monoclonal antibody	Phase 3 ARNASA failed to meet primary endpoint
Tezepelumab (Tezspire)	AstraZeneca / Amgen	Anti-TSLP — approved for severe asthma	Exploring COPD indication
Next-generation PDE inhibitors	Multiple sponsors	Refined PDE-3/4 selectivity	Phase 2 across multiple molecules
Inhaled JAK inhibitors	Multiple sponsors	Targeted anti-inflammatory pathway	Early phase

The pattern of mixed Phase 3 results in the IL-33 / ST2 / TSLP space is itself informative: inflammatory targets that work brilliantly in asthma do not always translate cleanly to COPD, where the underlying lung damage is structurally different. Tozorakimab's three-trial positive readout in April 2026 stands out as the most promising current development.

7.2 IPF and Pulmonary Fibrosis Pipeline

Drug	Sponsor	Mechanism	Status
Jascayd (nerandomilast)	Boehringer Ingelheim	PDE-4B inhibitor	FDA approved October 2025 — first new IPF drug in 10+ years
BMS-986278	Bristol Myers Squibb	LPA1 antagonist	Phase 3 ALOFT enrolling
Inhaled treprostinil	United Therapeutics	Prostacyclin analog	TETON-2 Phase 3 positive

Drug	Sponsor	Mechanism	Status
			(NEJM 2026)
Bexotegrast (PLN-74809)	Pliant Therapeutics	αvβ6 integrin inhibitor	Discontinued June 2025 (safety signal)
PRECISIONS Trial	Multi-center NIH	Precision-medicine approach to IPF	Active enrollment 2026

The discontinuation of bexotegrast in June 2025 — after promising early-phase data — is a reminder that IPF drug development remains difficult. Patients should be cautious about commercial 'stem cell' clinics offering unproven cellular therapies for IPF or COPD; legitimate cellular therapy research is being conducted in academic centers under FDA-regulated trials, not at pay-out-of-pocket clinics.

7.3 AI and Digital Health

- Machine-learning algorithms are being trained to predict COPD exacerbations days before they occur using wearable-sensor and smartphone data
- Smart inhalers (Propeller Health, Hailie) track usage and identify patients drifting toward an exacerbation
- Home spirometers integrated with apps now allow weekly home FEV_1 tracking
- Several Medicare Advantage plans now reimburse remote monitoring for moderate-severe COPD

7.4 Cellular and Regenerative Therapy — Honest Assessment

Stem cell therapy for COPD and IPF is one of the most heavily marketed and least evidence-supported treatments offered in the United States today. Patients pay substantial sums out of pocket for procedures with no demonstrated benefit and meaningful risk of complications including pulmonary embolism. Legitimate cellular therapy research is happening in academic centers under FDA-regulated trials — always free to the patient, always with informed consent, and never advertised on social media. If a cellular therapy clinic asks for upfront payment for chronic lung disease, that alone is a red flag.

8. CAREGIVER BURDEN AND PALLIATIVE CARE

Caring for someone with severe chronic lung disease is uniquely difficult — not because of the hours, but because of what the caregiver witnesses. Severe dyspnea distress is one of the most psychologically demanding symptoms in medicine, and family caregivers are at the front line of every flare.

8.1 The Numbers

77% of advanced COPD patients rely on informal (unpaid) caregivers

20–40 hrs/week typical informal caregiver time in moderate disease — much higher in oxygen-dependent patients

83% of COPD caregivers report leisure and social-life impairment

2x caregiver depression and anxiety rates versus age-matched non-caregivers

8.2 The Specific Psychological Toll of Dyspnea

Few medical symptoms are as distressing to witness as severe breathlessness. The patient gasps, the family panics, and the caregiver must decide in real time whether to call 911. Over years, this pattern wears down even the most dedicated caregiver. Caregivers describe vigilance — the constant readiness for the next emergency — as the most exhausting part of the role, more so than the actual physical care tasks.

8.3 Palliative Care and Hospice — Earlier Than Most Families Realize

Palliative care is not hospice. Palliative care is specialized medical care focused on symptom management and quality of life — alongside disease-directed treatment — for serious illness. It is appropriate for moderate-to-severe COPD years before end of life, and reduces hospitalizations, improves symptom control, and improves caregiver well-being.

Hospice is for the final 6 months of expected life. COPD is one of the most under-utilized hospice diagnoses — patients often enter hospice only in the last 1–2 weeks, missing months of available support. Eligibility criteria include FEV_1 less than 30%, oxygen dependence, frequent emergency-department visits, and progressive functional decline.

> *Talk with the pulmonologist about a palliative care consultation when mMRC reaches 3 or when the patient has had two or more hospitalizations in a year. Early palliative care is associated with longer survival, not shorter — and dramatically reduced caregiver burden.*

8.4 Where Caregivers Can Turn

- **COPD Foundation:** copdfoundation.org — patient and caregiver education, support communities, COPD360social peer network.
- **American Lung Association:** lung.org — Better Breathers Club support groups in many communities.
- **Pulmonary Fibrosis Foundation:** pulmonaryfibrosis.org — PFF Care Center Network, support groups, patient navigator.
- **Family Caregiver Alliance:** caregiver.org — general caregiver support resources, condition-specific fact sheets, respite guidance.
- **Eldercare Locator:** 1-800-677-1116 — federal helpline for local services including respite, adult day, and case management.
- **Area Agencies on Aging:** Local respite, transportation, meal delivery, home modification programs, and case management.
- **Veteran service organizations:** For eligible veterans, VA benefits include home health, respite, and caregiver support.

9. KEY RESOURCES

Organization	What They Offer	Website
Global Initiative for Chronic Obstructive Lung Disease (GOLD)	International clinical guidelines updated annually	goldcopd.org
American Lung Association	Patient education, advocacy, Better Breathers Clubs, quit-smoking help	lung.org
COPD Foundation	Patient-driven education, COPD360 social platform, exacerbation action plans	copdfoundation.org
American Thoracic Society (ATS)	Clinical guidelines and public patient education	thoracic.org
Pulmonary Fibrosis Foundation	IPF education, Care Center Network, patient navigator, registry	pulmonaryfibrosis.org
Alpha-1 Foundation	Alpha-1 antitrypsin deficiency advocacy, testing, and research	alpha1.org
Asthma and Allergy Foundation of America	Asthma education, action plans, advocacy	aafa.org
Bronchiectasis & NTM Initiative	Patient resources for bronchiectasis and NTM lung disease	ntminfo.org
NIH NHLBI	Research and patient education across all lung diseases	nhlbi.nih.gov
CDC COPD Page	Statistics, prevention resources, screening guidance	cdc.gov/copd
Smokefree.gov	Free quit coaching, text-message support, nicotine-replacement guidance	smokefree.gov
1-800-QUIT-NOW	State-funded telephone smoking-cessation counseling, free in all 50 states	1-800-784-8669

Organization	What They Offer	Website
ClinicalTrials.gov	Federal registry of active U.S. clinical trials for COPD, IPF, and asthma	clinicaltrials.gov
NAELA	Locate an elder law attorney for advance directives and healthcare proxy documents	naela.org
Family Caregiver Alliance	Caregiver education, support groups, condition-specific fact sheets	caregiver.org
Eldercare Locator	Federal helpline connecting older adults and families to local services (1-800-677-1116)	eldercare.acl.gov
Area Agencies on Aging (AAA)	Local case management, respite, adult day, home modification, transportation	eldercare.acl.gov

10. NEXT STEPS — RECOGNIZE, TREAT, PROTECT

> *Lung disease moves slowly enough that families almost always have planning time — if they recognize what is happening early enough to use it. The most preventable tragedy in chronic lung disease is the patient who was a former smoker, never had a spirometry test, never enrolled in pulmonary rehab, and never was offered the newer 2024–2025 medications — losing years of function that did not have to be lost.*

Whether you are a long-time smoker without symptoms, a newly diagnosed patient, or the adult child of a parent on home oxygen, the following steps protect what matters most:

Step 1 — Get Spirometry If You Have Any Risk

If you are or ever were a smoker, worked in an environment with dust or fumes, or have unexplained shortness of breath, ask your primary-care team for spirometry. It is a simple, non-invasive breathing test that catches COPD years before it would otherwise be diagnosed. Roughly half of Americans with COPD do not know they have it — a screening test is all it takes.

Step 2 — Stop Smoking; Get Every Recommended Vaccine

Smoking cessation is the single most powerful intervention in chronic lung disease. Combination nicotine replacement, varenicline, or bupropion — combined with brief counseling — doubles quit rates. Free coaching is available at 1-800-QUIT-NOW and smokefree.gov. In parallel, get flu, pneumococcal, RSV, COVID, Tdap, and shingles vaccines on schedule; respiratory infections are what turn stable disease into hospital admissions.

Step 3 — Enroll in Pulmonary Rehabilitation

Pulmonary rehab is the highest-yield action available for moderate-to-severe lung disease — reducing dyspnea, improving exercise tolerance, and cutting hospitalizations more than any medication. Medicare covers 36 sessions for qualifying patients. Yet only 3–5% of eligible patients ever enroll. If your pulmonologist or primary-care team has not offered a referral, ask specifically.

Step 4 — Ask About the 2024–2025 Medications

Three landmark COPD approvals — ensifentrine (Ohtuvayre), dupilumab (Dupixent), and mepolizumab (Nucala) — plus nerandomilast (Jascayd) for IPF have transformed the treatment landscape since 2024. If your diagnosis or last medication review predates these approvals, ask the pulmonologist: 'Should I be tested for eosinophils or type-2 inflammation, and would any of the newer therapies fit my situation?' Also confirm your inhaler technique with the pharmacist or respiratory therapist — poor technique is the single most common reason therapy fails.

Step 5 — Get an Alpha-1 Antitrypsin Test

Every patient with COPD should have a one-time alpha-1 antitrypsin blood test. About 1 in 25 COPD patients has this genetic condition, which is treated differently and often runs in families. It is inexpensive, painless, and easy to miss without asking.

Step 6 — Consider Palliative Care Early

Palliative care is not hospice — it is specialized symptom management and family support that runs alongside disease-directed treatment. In moderate-to-severe COPD or IPF, palliative care reduces hospitalizations, improves symptom control, and supports family decision-making. It is appropriate at mMRC Grade 3, or after two hospitalizations in a year — not just at end of life. Ask your pulmonologist for a referral.

Step 7 — Execute Legal Documents While You Have Capacity

Before advanced lung disease, respiratory failure, or an ICU admission, finalize:

- Durable Power of Attorney (financial) — allows a trusted person to manage finances if you cannot
- Health Care Proxy / Durable POA for Healthcare — allows a trusted person to make medical decisions
- Living Will / Advance Directive — specifies wishes for mechanical ventilation, tracheostomy, CPR, and comfort-focused care
- Will and trusts as appropriate — updated to reflect current circumstances

Advance directives are conversations, not just documents. Share them with the family members and clinicians who will need to honor them. After an ICU admission with prolonged ventilation, cognitive impairment can make signing new documents impossible for weeks or months.

Step 8 — Engage Your Medical Advocacy Team

Your most important allies are the pulmonologist, the primary-care physician or geriatrician, the respiratory therapist, the pharmacist, and — after hospitalization — the case manager and pulmonary rehab team. Ask directly for a written care plan that includes: exacerbation action plan (when to start prednisone or antibiotics, when to call, when to go to the emergency department), current inhaler regimen with technique check, oxygen requirements, and follow-up appointments. If your loved one is admitted for an exacerbation, ask whether the hospital has a COPD readmission-reduction program with post-discharge telephone follow-up.

Step 9 — Connect to Community and Caregiver Support

Contact your Area Agency on Aging (eldercare.acl.gov, 1-800-677-1116) for respite care, adult day programs, home modification help, transportation, and case management. Contact the Family Caregiver Alliance (caregiver.org) for caregiver education and support groups. Join a Better Breathers Club through

the American Lung Association or a COPD360 community through the COPD Foundation. Connection with others who have navigated advanced lung disease is consistently cited by families as one of the most valuable resources of the entire journey.

SOURCES & CITATIONS

1. *Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2026 GOLD Report — Global Strategy for Prevention, Diagnosis and Management of COPD. goldcopd.org*

2. *Centers for Disease Control and Prevention. COPD Statistics. cdc.gov/copd*

3. *CDC NCHS. Deaths: Leading Causes for 2023 — COPD ranked 5th. cdc.gov/nchs*

4. *American Thoracic Society / European Respiratory Society. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency.*

5. *Raghu G et al. Idiopathic Pulmonary Fibrosis: Evidence-Based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med.*

6. *ATS / ERS / JRS / ALAT Clinical Practice Guideline. Treatment of Idiopathic Pulmonary Fibrosis.*

7. *FDA. Ohtuvayre (ensifentrine) Approval, June 2024. fda.gov*

8. *FDA. Dupixent (dupilumab) COPD Approval, September 2024. fda.gov*

9. *FDA. Nucala (mepolizumab) COPD Approval, May 2025. fda.gov*

10. *FDA. Jascayd (nerandomilast) Approval for IPF, October 2025. fda.gov*

11. *Bhatt SP et al. Dupilumab for COPD with Type 2 Inflammation (BOREAS and NOTUS trials). NEJM 2023–2024.*

12. *Anzueto A, Miravitlles M. The Role of Ensifentrine in COPD Management. ENHANCE-1 and ENHANCE-2 trials.*

13. *Pavord ID et al. Mepolizumab for Eosinophilic COPD (MATINEE trial).*

14. *Richeldi L et al. Nerandomilast in Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF and FIBRONEER-ILD trials). NEJM 2025.*

15. *King TE Jr et al. A Phase 3 Trial of Pirfenidone in IPF (ASCEND). NEJM 2014.*

16. *Richeldi L et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis (INPULSIS). NEJM 2014.*

17. *Tozorakimab COPD program. AstraZeneca press releases. Phase 3 readouts April 2026.*

18. *Waschki B et al. Physical Activity Is the Strongest Predictor of All-Cause Mortality in Patients with COPD. Chest.*

19. *Vestbo J et al. Global Strategy for the Diagnosis, Management, and Prevention of COPD. ATS/ERS.*

20. *Casanova C et al. The 6-Minute Walk Distance in Healthy Subjects and Its Predictive Value in COPD.*

21. *Nici L et al. Pulmonary Rehabilitation: An Official ATS/ERS Statement.*

22. *Puhan MA et al. Pulmonary Rehabilitation Following Exacerbations of COPD (Cochrane Review).*

23. *Kohnlein T et al. Non-Invasive Positive Pressure Ventilation for the Treatment of Severe Stable COPD (Lancet Respir Med).*

24. *Criner GJ et al. A Multicenter RCT of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE).*

25. *Long-Term Oxygen Treatment Trial (LOTT) Research Group. NEJM 2016.*

> *DISCLAIMER: This white paper is provided for educational purposes only. It does not constitute medical advice or legal advice. Information about clinical trials and medications is current as of July 2026 and may change. Consult qualified medical and legal professionals for guidance specific to*

> *your situation.*